Barrett's oesophagus: Diagnosis and management

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 14, Issue 5, 2000, Pages 857-879

  Spechler, Stuart Jon ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Barrett's oesophagus; Gastro oesophageal reflux; Oesophageal neoplasms; Oesophagitis; Peptic

Indexed keywords

PROTON PUMP INHIBITOR;

ADENOCARCINOMA; ANTIREFLUX OPERATION; ARTICLE; BARRETT ESOPHAGUS; DYSPLASIA; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GENETIC DISORDER; HUMAN; INTESTINE METAPLASIA; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 0033793849     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2000.0129     Document Type: Article

References (134)

1. The columnar lined esophagus, intestinal metaplasia, and Norman Barrett
2. Morphology of Barrett's esophagus and Barrett's-associated dysplasia and adenocarcinoma
3. Laser photoablation of Barrett's epithelium: Burning issues about burning tissues
4. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
5. Short and ultrashort Barrett's esophagus: What does it mean?
6. The lower end of the oesophagus
7. Endoscopic features of the columnar-lined esophagus
8. Diagnostic inconsistencies in Barrett's esophagus
9. The histologic spectrum of Barrett's esophagus
10. The diagnosis of Barrett's esophagus: Goblets, goblets, goblets
11. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy
12. Prevalence of metaplasia at the gastro-oesophageal junction
13. The columnar lined oesophagus: A riddle wrapped in a mystery inside an enigma
14. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: Prevalence and clinical data
15. Short segment Barrett's esophagus: Clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia
16. Short segment Barrett's esophagus - The need for standardization of the definition and of endoscopic criteria
17. Early diagnosis of columnar-lined esophagus: A new endoscopic criterion
18. Intestinal metaplasia of the stomach. A status report
19. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction
20. What role does Helicobacter pylori play in gastric cancer?
21. Helicobacter pylori and gastric carcinogenesis
22. Helicobacter pylori in the stomach - Paradox unmasked
23. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils
24. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection
25. Helicobacter pylori and gastro-oesophageal reflux disease - A prospective study
26. Reflux oesophagitis and Helicobacter pylori infection in elderly patients
27. Esophagitis and Helicobacter pylori in children: Incidence and therapeutic implications
28. Campylobacter pylori and Barrett's esophagus
29. Helicobacter pylori in Barrett's esophagus
30. Prevalence and significance of Helicobacter pylori in patients with Barrett's esophagus
31. Barrett's oesophagus and Helicobacter pylori
32. Helicobacter pylori infection in patients with Barrett's oesophagus: A prospective immunohistochemical study
33. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis
34. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis
35. Prospective evaluation of the association of H. pylori infection with Barrett's dysplasia and Barrett's adenocarcinoma
36. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma
37. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease
38. pylori and cagA: Relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications
39. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centers
40. Subtypes of intestinal metaplasia and Helicobacteria pylori
41. Intestinal metaplasia types and the risk of gastric cancer: A cohort study in Slovenia
42. Gastric intestinal metaplasia type III cases are classified as low-grade dysplasia on the basis of morphometry
43. Scanning electron microscopy of Barrett's epithelium and its correlation with light microscopy and mucin stains
44. Mucin histochemistry of the columnar epithelium of the oesophagus: A retrospective study
45. Morphology of the columnar cell-lined (Barrett's) esophagus
46. Detection of a shared colon epithelial epitope on Barrett epithelium by a novel monoclonal antibody
47. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach
48. Cytokeratin profile suggests metaplastic epithelial transformation in Barrett's oesophagus
49. Distribution of cytokeratin markers in Barrett's specialized columnar epithelium
50. Barrett's esophagus
51. Columnar-lined esophagus in children
52. Esophageal acid sensitivity in Barrett's esophagus
53. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease
54. Risk factors for Barrett's esophagus in community-based practices
55. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings
56. Gastric acid hypersecretion in refractory gastroesophageal reflux disease
57. Elevated gastric acid secretion in patients with Barrett's metaplastic epithelium
58. Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus
59. Barrett's esophagus. Functional assessment, proposed pathogenesis, and surgical therapy
60. Esophageal function in patients with reflux-induced strictures and its relevance to surgical treatment
61. Role of salivary epidermal growth factor in the pathogenesis of Barrett's columnar lined oesophagus
62. Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls
63. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and degree of esophageal acid exposure
64. Barrett's esophagus: Age, prevalence, and extent of columnar epithelium
65. The increasing frequency of adenocarcinoma of the esophagus
66. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
67. Continuing climb in rates of esophageal adenocarcinoma: An update
68. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
69. The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years
70. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus
71. Adenocarcinoma in Barrett's oesophagus: An overrated risk
72. Barrett's esophagus: Should we brush off this ballooning problem?
73. Barrett's esophagus
74. Extended and limited types of Barrett's esophagus in the adult
75. Management of adenocarcinoma in a columnar-lined esophagus
76. The molecular basis for carcinogenesis in metaplastic columnar-lined esophagus
77. Dysplasia in Barrett's esophagus
78. Endoscopic surveillance for patients with Barrett's esophagus: Does the cancer risk justify the practice?
79. Complications of gastroesophageal reflux disease
80. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus
81. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia
82. Barrett's esophagus: Development of dysplasia and adenocarcinoma
83. Dysplasia in Barrett's esophagus. A clinicopathologic study of six patients
84. Barrett's high-grade dysplasia (HGD): Surveillance endoscopy (EGD) once a year (yr) is sufficient in most patients (pts)
85. Observer variation in the diagnosis of dysplasia in Barrett's esophagus
86. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus
87. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma
88. Barrett's esophagus. The significance of p53 in clinical practice
89. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort
90. Barrett's esophagus and adenocarcinoma: From the family to the gene
91. A study to examine agreement between endoscopy and histology for the diagnosis of columnar lined (Barrett's) esophagus
92. In vivo staining with toluidine blue as an adjunct to the endoscopic detection of Barrett's esophagus
93. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus
94. Combined magnification endoscopy with chromoendoscopy for the evaluation of Barrett's esophagus
95. Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia
96. High-resolution cross-sectional imaging of the gastrointestinal tract using optical coherence tomography: Preliminary results
97. Fluorescence endoscopy of gastrointestinal diseases: Basic principles, techniques, and clinical experience
98. Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus
99. The value of fluorescence techniques in gastrointestinal endoscopy: Better than the endoscopist's eye? I: The European experience
100. The value of fluorescence techniques in gastrointestinal endoscopy: Better than the endoscopist's eye? II: The North American experience
101. Long term continuous omeprazole treatment of patients with Barrett's oesophagus
102. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans
103. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis
104. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture
105. The rationale for continuous maintenance treatment of reflux esophagitis
106. Endoscopic regression of Barrett's esophagus during omeprazole treatment; a randomised, double blind study
107. New treatments for Barrett's esophagus
108. Squamous islands in Barrett's esophagus: What lies underneath?
109. Biomarker studies in reversed Barrett's esophagus
110. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model
111. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression
112. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors
113. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors
114. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus
115. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus
116. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects
117. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis
118. Gastric juice protects against the development of esophageal adenocarcinoma in the rat
119. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
120. Endoscopic surveillance of Barrett's esophagus. Does it help?
121. Endoscopic surveillance of Barrett's esophagus: A cost-effectiveness comparison with mammographic surveillance for breast cancer
122. A guide for surveillance of patients with Barrett's esophagus
123. Management of dysplasia in the columnar-lined esophagus
124. Barrett's esophagus
125. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: A review
126. Ablative therapies for the columnar-lined esophagus
127. Drug, light, and oxygen: A dynamic combination in the clinic
128. Photodynamic therapy for Barrett's esophagus: Follow-up in 100 patients
129. Initial results using low-dose photodynamic therapy in the treatment of Barrett's esophagus
130. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX
131. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid
132. Natural history of early esophageal squamous carcinoma and early adenocarcinoma of the gastric cardia in the People's Republic of China
133. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus